CLASS ACTION UPDATE for BIIB, YY and OTGLY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / January 5, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
BIIB Shareholders Click Here: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form?prid=11955&wire=1
YY Shareholders Click Here: https://www.zlk.com/pslra-1/joyy-inc-loss-submission-form?prid=11955&wire=1
OTGLY Shareholders Click Here: https://www.zlk.com/pslra-1/cd-projekt-s-a-loss-submission-form?prid=11955&wire=1
* ADDITIONAL INFORMATION BELOW *
Biogen Inc. (NASDAQ:BIIB)
BIIB Lawsuit on behalf of: investors who purchased October 22, 2019 - November 6, 2019
Lead Plaintiff Deadline: January 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form?prid=11955&wire=1
According to the filed complaint, during the class period, Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Joyy Inc. (NASDAQ:YY)
YY Lawsuit on behalf of: investors who purchased April 28, 2016 - November 18, 2020
Lead Plaintiff Deadline: January 19, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/joyy-inc-loss-submission-form?prid=11955&wire=1
According to the filed complaint, during the class period, Joyy Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) The majority of users at any given time were bots; (2) the Company utilized these bots to effect a roundtripping scheme that Manufactured the false appearance of revenues; (3) the Company overstated its cash reserves; (4) the Company's acquisition of Bigo was largely contrived to benefit corporate insiders; and (5) as a result, Defendants' public statements were materially false and/or Misleading at all relevant times.
CD Projekt S.A. (OTC PINK:OTGLY)
OTGLY Lawsuit on behalf of: investors who purchased January 16, 2020 - December 17, 2020
Lead Plaintiff Deadline: February 22, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cd-projekt-s-a-loss-submission-form?prid=11955&wire=1
According to the filed complaint, during the class period, CD Projekt S.A. made materially false and/or misleading statements and/or failed to disclose that: Throughout the class period, defendants were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company's business, operations and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Cyberpunk 2077 was virtually unplayable on the current-generation Xbox or Playstation systems due to an enormous number of bugs; (2) as a result, Sony would remove Cyberpunk 2077 from the Playstation store, and Sony, Microsoft and the Company would be forced to offer full refunds for the game; (3) consequently, the Company would suffer reputational and pecuniary harm; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/623246/CLASS-ACTION-UPDATE-for-BIIB-YY-and-OTGLY-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders